Top Markets
#1 Cortex Cortex +173.94%
#2 GEKKO GEKKO +50.71%
#3 Audiera Audiera +18.20%
#4 ADO Protocol ADO Protocol +17.37%
#5 Seeker Seeker +14.20%
#6 Pons Pons +14.13%
#7 TENDIES TENDIES +13.73%
#8 Siren Siren +12.81%
#9 o1.exchange o1.exchange +12.30%
#10 Helium Helium +11.78%
Coin of the day
Cortex Cortex
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Kedudukan dalam Saham #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Harga Saham
$14.07
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$1.18B
Perubahan (1 hari)
-4.41%
Perubahan (1 tahun)
145.13%
Negara
US
Perdagangan Corvus Pharmaceuticals, Inc. (CRVS)

Kategori

Healthcare
Sejarah dividen untuk Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (simbol saham: CRVS) telah membuat sejumlah 0 pembayaran dividen.
Jumlah semua dividen (disesuaikan untuk pemecahan saham): 0.00
Hasil dividen (TTM): 0
Pembayaran dividen untuk Corvus Pharmaceuticals, Inc. (CRVS) dari 2026 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (diselaraskan untuk pemecahan saham) Ubah
Tidak cukup data untuk tarikh yang disediakan.
Senarai semua pembayaran dividen
Tahun Dividen Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pembayaran dividen untuk syarikat serupa atau pesaing
Syarikat Jumlah pembayaran dividen Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH